- Goldman is out with some new estimates for Pharmacyclics' (PCYC) Ibrutinib.
- Analyst Navdeep Singh sees a $5B opportunity in CLL and a $2.5B opportunity in MCL, WM, and DLBCL.
- Singh's price target is upped to $170 (from $111), representing a 38% premium to Thursday's close.
- Optimism surrounding Ibrutinib has reached a fever pitch, and some estimates peg the drug's potential as high as $9B.
- PCYC +6.3% premarket.